APOE and Alzheimer disease: Current evidence suggests that APOE ε4 shifts the age at which AD pathology begins to accumulate in a dose‐dependent manner, with ε4 homozygous individuals having the youngest age at onset of amyloid accumulation and positivity, followed by ε4 heterozygous individuals and then ε4 noncarriers.39